Liraglutide vs Mazdutide

Liraglutide and Mazdutide are both research peptides investigated for metabolic disorders, yet they occupy distinct positions in the therapeutic landscape. Liraglutide, a GLP-1 receptor agonist with high homology to endogenous GLP-1, has been extensively validated in clinical settings for type 2 diabetes and obesity. Mazdutide, a dual GLP-1/glucagon receptor agonist, introduces a novel mechanism that targets both appetite suppression and energy expenditure. This overview highlights their key differences: Liraglutide benefits from a robust evidence base and regulatory approvals, while Mazdutide offers a dual-action profile with potential advantages in hepatic fat reduction and weight loss efficacy. Researchers must weigh these factors against the maturity of safety data and dosing convenience.

Liraglutide functions as a GLP-1 receptor agonist with 97% amino acid sequence homology to endogenous human GLP-1, developed by Novo Nordisk and approved as Victoza for type 2 diabetes and Saxenda for chronic weight management. It was the first GLP-1 agonist approved for obesity, marking a milestone in metabolic research. However, its clinical utility has been partially eclipsed by semaglutide, which offers once-weekly dosing and superior weight loss outcomes—approximately 8% weight loss with liraglutide compared to 15% with semaglutide in head-to-head trials. Key research findings include clinically significant weight loss, improved glycemic control, and cardiovascular benefits, supported by extensive randomized controlled trials. Liraglutide's daily injection requirement and moderate efficacy profile make it a benchmark comparator in studies exploring newer agents like Mazdutide.

Mazdutide (IBI362) is a dual GLP-1/glucagon receptor agonist co-developed by Innovent Biologics and Eli Lilly (MW 4,563.06 g/mol). It is a once-weekly injectable peptide that activates both GLP-1 and glucagon receptors, aiming to combine GLP-1-mediated appetite suppression and glucose lowering with glucagon-mediated increases in energy expenditure and hepatic fat reduction. China's NMPA approved mazdutide in June 2025 for chronic weight management and in September 2025 for glycaemic control in type 2 diabetes, making it the first dual GLP-1/glucagon agonist approved anywhere in the world.

Key claims: Significant weight loss in Chinese adults with obesity; Effective glycemic control; Reduces hepatic fat content.

Both peptides are investigated for weight management and metabolic health, reflecting their shared capacity to modulate appetite and glucose homeostasis. Liraglutide is additionally studied for cardiovascular outcomes, leveraging its established benefits on major adverse cardiovascular events (MACE) in type 2 diabetes populations. Mazdutide, while not yet linked to cardiovascular endpoints in large trials, is uniquely explored for hepatic fat reduction, which may address metabolic liver disease. The overlap in applications allows researchers to compare the relative efficacy of single versus dual receptor agonism in obesity and glycemic control, while the divergent areas highlight Mazdutide's potential niche in liver-related metabolic disorders.

Liraglutide's safety profile is well-characterized from extensive clinical use. Common adverse events include nausea (39%), diarrhea (21%), constipation (19%), vomiting (15%), and headache (13%), with gastrointestinal effects being dose-dependent and typically diminishing over weeks. A FDA black box warning exists for thyroid C-cell tumors based on rodent data, though relevance to humans remains uncertain. Mazdutide exhibits a similar gastrointestinal side effect profile—nausea, vomiting, diarrhea—consistent with GLP-1 agonist class effects, which are dose-dependent and generally transient. Additionally, heart rate increases have been observed, aligning with GLP-1 agonist class effects. The safety data for Mazdutide is less mature, given its recent approval and ongoing trials, necessitating cautious interpretation in preclinical research contexts.